Stocktoria
Enliven Therapeutics, Inc. ELVN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-03-12
Chart by TradingView
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Valuation · market cap as of 2026-06-29
Market cap$3.6B
P / B7.8×
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$119.7M | -$104.6M | -$83.5M | -$38.8M | -$51.4M |
| Net income | -$103.7M | -$89.0M | -$71.6M | -$37.7M | -$51.4M |
| Operating cash flow | -$70.3M | -$73.2M | -$61.3M | -$32.1M | -$46.8M |
| Total assets | $476.2M | $325.8M | $271.9M | $83.3M | $93.6M |
| Total liabilities | $16.6M | $15.9M | $26.0M | $10.4M | $7.6M |
| Shareholders' equity | $459.6M | $309.8M | $245.9M | -$76.8M | -$42.9M |
| Ratios | |||||
| Return on assets | -21.8% | -27.3% | -26.3% | -45.2% | -54.9% |
| Return on equity | -22.6% | -28.7% | -29.1% | 49.0% | 119.8% |
| Current ratio | 28.66 | 19.99 | 10.28 | 8.00 | 12.86 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 39,600 | $1.6M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001672619 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.